AndreCKalilMD
Infectious Disease • Omaha, NEAssociate Professor, Internal Medicine, University of Nebraska Medical Center College of Medicine
Are you Dr. Kalil?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 76 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
988102 Nebraska Medical Ctr
Omaha, NE 68198Phone+1 402-559-4015Fax+1 402-559-5581
Summary
- Dr. Andre Kalil, MD is an infectious disease specialist in Omaha, Nebraska. He is currently licensed to practice medicine in Nebraska, District of Columbia, and Maryland. He is affiliated with Nebraska Medicine - Nebraska Medical Center and is an Associate Professor at University of Nebraska Medical Center College of Medicine.
Education & Training
Massachusetts General Hospital/Brigham and Women's Hospital/Harvard Medical SchoolFellowship, Infectious Disease, 1996 - 1998
National Institutes of Health Clinical CenterFellowship, Critical Care Medicine (Internal Medicine), 1995 - 1996
University of Miami/Jackson Health SystemResidency, Internal Medicine, 1991 - 1995
Certifications & Licensure
NE State Medical License 2002 - 2026
MA State Medical License 1996 - 2001
DC State Medical License 1998 - 2000
FL State Medical License 1993 - 2000
MD State Medical License 1997 - 2000- American Board of Internal Medicine Infectious Disease
Clinical Trials
- Procalcitonin and Endotoxin Sequential Levels to Optimize the Treatment of Bloodstream Infections Start of enrollment: 2009 Jun 01
- Adaptive COVID-19 Treatment Trial (ACTT) Start of enrollment: 2020 Feb 21
- Safety, Tolerability, and Pharmacokinetics of SAB-185 in Ambulatory Participants With COVID-19 Start of enrollment: 2020 Aug 20
- Join now to see all
Publications & Presentations
PubMed
- Sepsis: A Summary of the SEP-1 Quality Measure and Future Considerations.Sias J Scherger, Andre C Kalil
Clinical Microbiology and Infection. 2024-12-21 - Seven versus 14 days of antimicrobial therapy for severe multidrug-resistant Gram-negative bacterial infections in intensive care unit patients (OPTIMISE): a randomise...Beatriz Arns, Andre C Kalil, Guilherme G L Sorio, Emerson Boschi, Ana Carolina Peçanha Antonio
Critical Care. 2024-12-18 - 1 citationsRemdesivir Effectiveness in Reducing the Risk of 30-Day Readmission in Vulnerable Patients Hospitalized for COVID-19: A Retrospective US Cohort Study Using Propensity ...Essy Mozaffari, Aastha Chandak, Robert L Gottlieb, Andre C Kalil, Heng Jiang
Clinical Infectious Diseases. 2024-12-13
Press Mentions
Remdesivir-Dexamethasone Tied to Fewer Deaths in Severe COVIDSeptember 24th, 2024- Steroid Drug Reduces Death Rate in Severe Pneumonia, Study ShowsMarch 21st, 2023
- FDA Approves Lilly and Incyte's OLUMIANT® (Baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19May 11th, 2022
- Join now to see all
Professional Memberships
- Member
